Use

Guardant360® Liquid is a next‑generation sequencing (NGS)-based liquid biopsy test that analyzes circulating tumor DNA (ctDNA) to deliver comprehensive genomic and epigenomic insights for advanced solid tumors, helping guide personalized therapy selection. It is a fast comprehensive genomic profiling panel with guideline‑recommended actionable biomarkers, enabling oncologists to detect actionable somatic alterations in a minimally invasive manner and monitor tumor evolution. [Summarized]